

PROGRAM TITLE The Evolution of Anticoagulant Therapy in ACS
(An educational program for pharmacists and pharmacy technicians)

LOCATION **C & O Restaurant**
515 East Water Street
Charlottesville, VA 22901

DATE/ TIME Thursday August 28, 2008 Program/ Dinner: 6:30-8:30 PM
Please RSVP by August 21, 2008

COORDINATING ORGANIZATION Region I, Virginia Society of Health-System Pharmacists
Sponsor: University Pharmacotherapy Associates, LLC

MEETING Free to VSHP members

LOCAL CONTACT Meg Taylor, Pharm.D., BCPS
Email UPA: www.upa-llc.com/rsvpform.htm or fax 412-380-8597
include location, date and time in message
RSVP by Thursday, August 21 2008

Speaker **Cynthia A. Sanoski, B.S., Pharm.D.**
*Chair, Department of Pharmacy Practice
Jefferson School of Pharmacy
Thomas Jefferson University
Philadelphia, PA*

Objectives: Learning objectives
Upon completion of this program, the participant will be able to:

- 1) Differentiate unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), fondaparinux, and bivalirudin pharmacology.
- 2) Review current anticoagulant efficacy and safety evidence and practice guidelines in defining contemporary practice in unstable angina/non-ST segment elevation MI (UA/NSTEMI).
- 3) Assess evolving anticoagulant evidence with invasive treatment in ST segment elevation MI (STEMI).
- 4) Discuss contemporary anticoagulation issues in ACS (e.g., bleeding sequelae, dosing, economics).



University Pharmacotherapy Associates, LLC, is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of pharmacy continuing education and complies with the criteria for quality continuing pharmacy education programming. This program provides 1 hour (0.1 CEU) of continuing pharmacy education credit (ACPE UPN 786-000-08-004-L01-P). Upon attendance of the entire program and completion of appropriate forms, statements of continuing education will be issued within 45 days of completion of the program.